Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jun;140(3):507-16.
doi: 10.1111/j.1365-2249.2005.02791.x.

Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia

Affiliations

Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia

A Stray-Pedersen et al. Clin Exp Immunol. 2005 Jun.

Abstract

The immunodeficiency in Ataxia-telangiectasia (A-T) is characterised by low T and B cell counts, low levels of IgE, IgA and/or IgG2, and especially low levels of pneumococcal antibodies. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has previously been shown not to be effective in A-T, but these patients are capable of making protective antibodies to other vaccines such as diphtheria and tetanus toxin, promising effect of the seven-valent pneumococcal conjugated vaccine (PCV7). Nine A-T patients and 25 age and sex matched controls were vaccinated with both PCV7 and PPV23, and three A-T patients were vaccinated with PCV7 only. In the A-T patients, no significant increase in pneumococcal antibody levels were observed after the single PCV7, while the subsequent PPV23 vaccination resulted in a significant increase in antibody levels to the PPV23 mix, as well as to serotype 4, 14, 19F and to the geometric mean of serotype 4, 6B, 14, 18C, 19F, 23F which increased from median 0.2 (range 0.1-0.5) microg/mL to 0.6 (0.2-1.5) microg/mL (P= 0.014). Compared to the patients' baseline levels, the vaccinations induced a 1.5- to 7-fold increase in antibodies to the six different serotypes tested. The increases in pneumococcal antibody titres were lower than those observed in the controls (9- to 34-fold increase). The results are valuable in planning the care of A-T patients, using PCV7 to trigger and PPV23 to booster the immune response and possibly prevent severe pneumococcal disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Age distribution among A-T patients and controls.
Fig. 2
Fig. 2
Pneumococcal antibodies measured before and after immunization with PCV7 and PPV23 in patients and controls. Be aware that the y-axes are log transformed and may vary from serotype to serotype.
Fig. 2
Fig. 2
Pneumococcal antibodies measured before and after immunization with PCV7 and PPV23 in patients and controls. Be aware that the y-axes are log transformed and may vary from serotype to serotype.

Similar articles

Cited by

References

    1. Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22–23. Nature. 1988;336:577–80. - PubMed
    1. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53. - PubMed
    1. Schubert R, Reichenbach J, Zielen S. Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia. Clin Exp Immunol. 2002;129:125–32. - PMC - PubMed
    1. Stray-Pedersen A, Jónsson T, Heiberg A, et al. The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents. Clin Exp Immunol. 2004;137:178–86. - PMC - PubMed
    1. Dhooge IJ, van Kempen MJ, Sanders LA, Rijkers GT. Deficient IgA and IgG2 anti-pneumococcal antibody levels and response to vaccination in otitis prone children. Int J Pediatr Otorhinolaryngol. 2002;64:133–41. - PubMed

Publication types

MeSH terms